Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Summary

This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the adjuvants on the immune response. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and skin tissue.

Timeline

Start

2020-09-28

Primary completion

2024-03-14

Completion

2024-03-14

Publications

• Ninmer EK, Petroni GR, Gastman BR, Gaughan EM, Isaacs JM, Haden K, Kaur V, Wages NA, Chianese-Bullock KA, Smith KT, Wright P, Bryant J, Dunlap-Brown M, Engel JA, Bekiranov S, Mauldin IS, Truong TG, Bullock TNJ, Slingluff CL Jr. Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC). J Immunother Cancer. 2026 Mar 3;14(3):e013613. doi: 10.1136/jitc-2025-013613.

Drugs

Indications